CING
$11.66
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States.
Recent News
Cingulate price target lowered to $16 from $17 at Roth Capital
Roth Capital analyst Boobalan Pachaiyappan lowered the firm’s price target on Cingulate (CING) to $16 from $17 and keeps a Buy rating on the shares after meeting with its management to discuss Q3 results. The company is ratcheting up its CTx-1301 U.S. pre-commercialization efforts through its Indegene partnership, though the firm is adjusting its model on expectation that Cingulate may choose to raise capital during the next 6 to 12 months, the analyst tells investors in a research note.TipRanks
Cingulate secures $3m to advance once-daily anxiety treatment
The grant will be distributed in three $1m tranches, with the first payment scheduled for 1 May 2025.